Fidelity Investments
SGMO

Fidelity Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Fidelity Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.3K Sell
244,139
-21,269
-8% -$8.46K ﹤0.01% 4036
2025
Q4 		$111K Buy
265,408
+12,528
+5% +$6.64K ﹤0.01% 3704
2025
Q3 		$170K Sell
252,880
-329,456
-57% -$178K ﹤0.01% 3432
2025
Q2 		$315K Buy
582,336
+19,400
+3% +$11.5K ﹤0.01% 3141
2025
Q1 		$369K Sell
562,936
-15,329
-3% -$16.2K ﹤0.01% 3011
2024
Q4 		$590K Buy
578,265
+34,262
+6% +$62.6K ﹤0.01% 2859
2024
Q3 		$471K Buy
544,003
+77,032
+16% +$56.4K ﹤0.01% 2880
2024
Q2 		$167K Buy
466,971
+30,316
+7% +$16.4K ﹤0.01% 3093
2024
Q1 		$293K Buy
436,655
+125,123
+40% +$90.8K ﹤0.01% 2890
2023
Q4 		$169K Buy
311,532
+25,285
+9% +$11.7K ﹤0.01% 3016
2023
Q3 		$172K Sell
286,247
-2,445
-0.8% -$2.62K ﹤0.01% 2933
2023
Q2 		$375K Buy
288,692
+164,861
+133% +$225K ﹤0.01% 2748
2023
Q1 		$218K Buy
123,831
+3,020
+2% +$8.62K ﹤0.01% 2944
2022
Q4 		$379K Sell
120,811
-2,309
-2% -$8.96K ﹤0.01% 2805
2022
Q3 		$604K Buy
123,120
+3,053
+3% +$15.7K ﹤0.01% 2734
2022
Q2 		$497K Buy
120,067
+652
+0.5% +$2.82K ﹤0.01% 2849
2022
Q1 		$694K Buy
119,415
+38,088
+47% +$226K ﹤0.01% 2884
2021
Q4 		$610K Sell
81,327
-223,023
-73% -$1.94M ﹤0.01% 2757
2021
Q3 		$2.74M Sell
304,350
-56,378
-16% -$557K ﹤0.01% 2504
2021
Q2 		$4.32M Sell
360,728
-142,399
-28% -$1.61M ﹤0.01% 2372
2021
Q1 		$6.3M Buy
503,127
+129,500
+35% +$1.75M ﹤0.01% 2189
2020
Q4 		$5.83M Sell
373,627
-388,200
-51% -$4.55M ﹤0.01% 2140
2020
Q3 		$7.2M Sell
761,827
-66,600
-8% -$720K ﹤0.01% 1939
2020
Q2 		$7.42M Buy
828,427
+300
+0% +$2.78K ﹤0.01% 1919
2020
Q1 		$5.28M Sell
828,127
-1,193,200
-59% -$8.85M ﹤0.01% 1921
2019
Q4 		$16.9M Sell
2,021,327
-422,223
-17% -$3.88M ﹤0.01% 1656
2019
Q3 		$22.1M Sell
2,443,550
-235,900
-9% -$2.65M ﹤0.01% 1536
2019
Q2 		$28.9M Buy
2,679,450
+234,700
+10% +$2.5M ﹤0.01% 1473
2019
Q1 		$23.3M Sell
2,444,750
-16,400
-0.7% -$167K ﹤0.01% 1537
2018
Q4 		$28.3M Sell
2,461,150
-194,955
-7% -$2.42M ﹤0.01% 1416
2018
Q3 		$45M Sell
2,656,105
-662,945
-20% -$10.1M 0.01% 1326
2018
Q2 		$47.1M Sell
3,319,050
-932,409
-22% -$15.5M 0.01% 1303
2018
Q1 		$80.8M Sell
4,251,459
-1,103,962
-21% -$23.6M 0.01% 1073
2017
Q4 		$87.8M Buy
5,355,421
+2,511,532
+88% +$37.4M 0.01% 1056
2017
Q3 		$42.7M Buy
2,843,889
+1,232,806
+77% +$13.6M 0.01% 1379
2017
Q2 		$14.2M Hold
1,611,083
– – ﹤0.01% 1812
2017
Q1 		$8.38M Sell
1,611,083
-92,700
-5% -$372K ﹤0.01% 2035
2016
Q4 		$5.2M Hold
1,703,783
– – ﹤0.01% 2170
2016
Q3 		$7.89M Sell
1,703,783
-1,325,900
-44% -$6.74M ﹤0.01% 2072
2016
Q2 		$17.5M Hold
3,029,683
– – ﹤0.01% 1734
2016
Q1 		$18.3M Sell
3,029,683
-1,210,100
-29% -$7.27M ﹤0.01% 1702
2015
Q4 		$38.7M Sell
4,239,783
-250,000
-6% -$1.93M 0.01% 1361
2015
Q3 		$25.3M Buy
4,489,783
+219,968
+5% +$1.81M ﹤0.01% 1560
2015
Q2 		$47.4M Buy
4,269,815
+49,134
+1% +$633K 0.01% 1354
2015
Q1 		$66.2M Buy
4,220,681
+120,706
+3% +$1.87M 0.01% 1220
2014
Q4 		$62.4M Sell
4,099,975
-2,022,800
-33% -$24.6M 0.01% 1230
2014
Q3 		$66M Hold
6,122,775
– – 0.01% 1171
2014
Q2 		$93.5M Hold
6,122,775
– – 0.01% 1036
2014
Q1 		$111M Buy
6,122,775
+1,817,175
+42% +$35M 0.02% 929
2013
Q4 		$59.8M Buy
4,305,600
+571,500
+15% +$6.58M 0.01% 1227
2013
Q3 		$39.1M Buy
3,734,100
+1,685,000
+82% +$16.7M 0.01% 1399
2013
Q2 		$16M Buy
+2,049,100
New +$17.9M ﹤0.01% 1742

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Fidelity Investments's SGMO Position: Q1 2026 in Review

Fidelity Investments reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 8% in Q1 2026, selling an estimated $8.46K and leaving 244,139 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

Fidelity Investments first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $111M in Q1 2014. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Fidelity Investments held 244,139 shares of SANGAMO THERAPEUTICS INC worth $60.3K as of Q1 2026.
  • Fidelity Investments sold 21,269 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $8.46K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4036 holding.
  • Fidelity Investments first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Fidelity Investments's SANGAMO THERAPEUTICS INC position peaked at $111M in Q1 2014.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.